Media Coverage
Artificial intelligence and machine learning are changing the pharmaceutical sector, affecting drug discovery, clinical trials, and other areas, according to a report by Stifel that used Dealforma’s data. Checkout the Stifel story
DealForma’s Chris Dokomajilar has been running the numbers again and backs up some of the things we were already pretty sure about — while raising new questions about just how deep and lasting this biotech recovery can be. Checkout the Endpoints News story
Tim Opler and the team at Stifel put together a chart-packed weekly report on biopharmaceutical sector. DealForma was happy to contribute the data.
In January 2024, the rare disease therapeutics sector experienced a funding surge to nearly $3 billion, indicating a strong start to the year.
Endpoints News’ John Carroll and DealForma’s Chris Dokomajilar hosted a special webinar to discuss their latest ranking of the top 100 biotech VCs, examining the challenges and opportunities in a market facing an IPO drought and investor hesitancy. Listen to the webinar here.
Chris Dokomajilar from DealForma joins this podcast by RX for Biotech to explore the investment trends in advanced therapies and AI within biopharma, using insights from DealForma’s detailed life science database.
John Carroll talks about the Q4 2023 biotech sector in a report that reveals a significant uptick in mergers and acquisitions, highlighting a change towards growth amid valuation and economic headwinds.
J.P. Morgan utilized Dealforma’s comprehensive data to compile their 2023 Annual Biopharma Licensing and Venture Report, highlighting key trends in funding, mergers, acquisitions, and more within the biopharma sector.
Utilizing DealForma’s data, Nature’s article showcases selected deals focusing on cardiovascular diseases, CNS disorders, and the oligonucleotide therapies driving these advancements.
In January 2024, the rare disease therapeutics sector experienced a funding surge to nearly $3 billion, indicating a strong start to the year.
